[1] Bladder cancer is usually stratified into two broad categories: papillary superficial and solid invasive tumors. Superficial tumors are the most frequent of all newly diagnosed bladder cancers ...

Background: A 59-year-old female presented with a history of recurrent superficial bladder cancer. Since the initial ... she presented with several papillary lesions throughout the bladder ...

Some patients with low-grade Ta nonmuscle-invasive bladder cancer (LG Ta NMIBC) can experience recurrence after many years.

They are also anticipating submitting a supplemental application in the United States to extend approval to include patients with papillary bladder cancer, rather than just those patients with ...

for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...

for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The drug is combined with the BCG vaccine, mainly used against ...

BCG unresponsive non-muscle invasive bladder cancer (NMIBC) in the papillary indication: Anticipated supplemental biologics license application (BLA) submission in 2025 Alternative source of BCG ...

The drugmaker is seeking to have the therapy approved for the treatment of Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or ...

J&J on Wednesday said the application covers TAR-200 in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in the EU and the United Kingdom for Anktiva (nogapendekin alfa inbakicept) in ...

On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer ...